 This study will evaluate the safety and tolerability of escalating single- and multiple-oral doses of GS-9674, and characterize the single- and multiple-dose pharmacokinetics PK of GS-9674. The study will be conducted in 3 parts Part A, Part B, and Part C. Participants will receive either GS-9674 or GS-9674 placebo. 